EVOK

Evoke Pharma, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website evokepharma.com
Employees(FY) 4
ISIN US30049G3020

Performance

-8.8%

-17.24%

-23.36%

-18.28%

-63.82%

YTD

-69.48%

Profile

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Advanced Technical Analysis

Technical Analysis of EVOK 2024-11-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 40 suggesting a neutral stance, and a Technical Score of 25 reinforcing the overall bearish outlook. This combination signals caution for potential investors as the market appears to be un...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of EVOK

Stock Rank

Recent News & Updates

2024-11-07 03:05
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-10-28 01:39
Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis(Yahoo Finance)
2024-10-27 19:00
Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI(Globenewswire)
2024-10-22 20:30
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting(Globenewswire)
2024-10-21 20:30
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors(Globenewswire)
2024-09-30 20:30
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion(Globenewswire)
2024-09-20 14:38
Nantahala Capital Management's Recent Transaction in Evoke Pharma Inc(Yahoo Finance)
2024-09-19 02:20
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments(Globenewswire)
2024-09-08 20:30
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference(Globenewswire)
2024-09-03 21:20
Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference(Globenewswire)
2024-08-12 20:00
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results(Globenewswire)
2024-08-07 20:30
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month(Globenewswire)
2024-07-29 20:30
Evoke Pharma, Inc. Announces Reverse Stock Split(Globenewswire)
2024-06-16 20:30
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI(Globenewswire)
2024-05-16 04:02
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference(Globenewswire)
2024-05-14 10:53
EVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-14 04:15
Evoke Pharma Reports First Quarter 2024 Financial Results(Globenewswire)
2024-04-16 20:30
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications(Globenewswire)
2024-03-21 04:15
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer(Globenewswire)
2024-03-15 01:58
Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript(Insidermonkey)
2024-03-14 18:56
Q4 2023 Evoke Pharma Inc Earnings Call(Yahoo Finance)
2024-03-14 04:05
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results(Globenewswire)
2024-03-07 03:10
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024(Globenewswire)
2024-02-13 18:30
Evoke Pharma Announces Closing of $7.5 Million Public Offering(Globenewswire)
2024-02-08 18:30
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million(Globenewswire)
2023-11-29 23:16
Revolutionizing gastroparesis treatment: Evoke Pharma's CEO talks game-changing nasal spray(Yahoo Finance)
2023-11-26 19:30
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent(Globenewswire)
2023-11-13 19:30
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI(Globenewswire)
2023-11-08 19:30
Evoke Pharma Reports Third Quarter 2023 Financial Results(Globenewswire)
2023-10-30 20:30
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.